SCHEMBL4293116

SCHEMBL4293116

CC[C@H](NC(=O)c1cc(-c2ccc3[nH]ncc3c2)on1)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 11/20 0.64
GSK3B P49841 4/20 0.64
PIM1 P11309 3/20 0.64
ROCK1 Q13464 11/20 0.51
DYRK1A Q13627 4/20 0.51
AURKA O14965 3/20 0.51
DAPK3 O43293 3/20 0.51
JAK2 O60674 3/20 0.51
GSK3A P49840 3/20 0.51
CDK5 Q00535 3/20 0.51
AURKB Q96GD4 3/20 0.51
CDK2 P24941 2/20 0.51
MARK3 P27448 2/20 0.51
FGFR1 P11362 2/20 0.51
PRKACA P17612 2/20 0.51
KDR P35968 2/20 0.51
CDK1 P06493 1/20 0.51
RPS6KB1 P23443 1/20 0.51
MAPK1 P28482 1/20 0.51
FLT4 P35916 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3640248 1.00 ROCK2 (0.64) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL3636925 1.00 ROCK2 (0.64) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL4289901 0.91 ROCK2 (0.62) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL3632578 0.91 ROCK2 (0.62) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL4298337 0.90 ROCK2 (0.60) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL4288861 0.90 ROCK2 (0.60) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL3667515 0.88 ROCK2 (0.59) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL4285228 0.87 ROCK2 (0.68) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL4291905 0.87 ROCK2 (0.68) ROCK2GSK3BPIM1ROCK1DYRK1A
SCHEMBL3635151 0.86 ROCK2 (0.56) ROCK2GSK3BPIM1ROCK1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885GSK3B 1/4885PIM1 11/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885GSK3B 1/4885PIM1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.